[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,176,544
  • Shares Outstanding, K 214,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,131 M
  • EBIT $ -1,627 M
  • EBITDA $ -1,639 M
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.24

Options Overview Details

View History
  • Implied Volatility 45.52% (-3.87%)
  • Historical Volatility 37.70%
  • IV Percentile 4%
  • IV Rank 8.76%
  • IV High 129.42% on 04/10/26
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 22) 17.85 (8.07%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 4,620
  • Volume Avg (30-Day) 2,644
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 66,522
  • Open Int (30-Day) 69,053
  • Expected Range 203.30 to 239.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-2.33
  • Number of Estimates 10
  • High Estimate $-1.97
  • Low Estimate $-2.57
  • Prior Year $-1.61
  • Growth Rate Est. (year over year) -44.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
178.07 +24.19%
on 07/29/26
224.31 -1.41%
on 08/27/26
+33.08 (+17.59%)
since 07/27/26
3-Month
141.44 +56.36%
on 06/10/26
224.31 -1.41%
on 08/27/26
+68.15 (+44.54%)
since 05/27/26
52-Week
37.56 +488.79%
on 08/29/25
224.31 -1.41%
on 08/27/26
+183.11 (+481.36%)
since 08/27/25

Most Recent Stories

More News
FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer

RVMD : 221.15 (+2.65%)
Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution

NEW YORK , Aug. 26, 2026 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, September 10, 2026,...

DKNG : 24.22 (-2.26%)
CRDO : 240.24 (+6.07%)
TTD : 13.42 (+2.99%)
CRS : 490.58 (+1.42%)
FIG : 30.62 (+13.28%)
CSGP : 31.34 (-2.49%)
ERIE : 259.44 (+0.84%)
IT : 196.60 (+1.89%)
AER : 147.97 (-1.24%)
DPZ : 332.05 (-3.63%)
APTV : 45.44 (-1.79%)
SUNB : 73.66 (-0.97%)
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic...

RVMD : 221.15 (+2.65%)
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

This release contains multimedia assets available for download here

RVMD : 221.15 (+2.65%)
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers ...

ONC : 372.49 (-0.88%)
RVMD : 221.15 (+2.65%)
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results Rapidly implemented U.S. Expanded...

RVMD : 221.15 (+2.65%)
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute...

RVMD : 221.15 (+2.65%)
Revolution Medicines: The First Test of Whether RAS Optimism Justifies Biotech Premium

Barchart Research What to Expect from RVMD Earnings RVMD Generated August 4, 2026 Current Price $193.46 EPS Estimate $$-1.93 Consensus Rating Strong Buy Average Move 3.86% Revolution Medicines: The First...

RVMD : 221.15 (+2.65%)
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 221.15 (+2.65%)
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 221.15 (+2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 233.11
2nd Resistance Point 228.71
1st Resistance Point 224.93
Last Price 221.15
1st Support Level 216.75
2nd Support Level 212.35
3rd Support Level 208.57

See More

52-Week High 224.31
Last Price 221.15
Fibonacci 61.8% 152.97
Fibonacci 50% 130.93
Fibonacci 38.2% 108.90
52-Week Low 37.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.